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Available online 4 August 2016Objective: To investigate the utility of a blood-based lab test as an aid in identifying patients with Multiple Scle-
rosis (MS).
Methods:Whole blood from subjects withMS, non-MS neurologic diseases, and healthy controlswas centrifuged
to isolate erythrocytes. Following the addition of exogenous C-peptide, the supernatant was assayed for remain-
ing C-peptide using an enzyme linked immunosorbent assay (ELISA).
Results: The cohort included subjects with MS (n = 86), other non-MS neurologic diseases (OND n = 75), and
healthy controls (n = 39). The average C-peptide bound to erythrocytes in MS samples (3.51 ± 0.59 pmol)
was signiﬁcantly higher than non-MS subjects (2.23 ± 0.51 pmol; p b 0.001) and healthy controls (1.99 ±
0.32 pmol; p b 0.001). Using a cutoff of 3.04 pmol of C-peptide uptake, the test exhibited a sensitivity of 98.3%
and speciﬁcity of 89.5%. A receiver-operator characteristic (ROC) curve generated from the ratio of the sensitivity
to 1-selectivity resulted in an area under the curve of 0.97.
Conclusions: Exogenous C-peptide binding to erythrocytes has potential value in distinguishingMS subjects from
non-MS neurologic diseases and healthy controls.






It is estimated by theNationalMultiple Sclerosis Society that over 2.3
million people worldwide have Multiple Sclerosis (MS) and that ap-
proximately 250,000 to 350,000 live in the United States. It is also esti-
mated that nearly 10,000 new cases are diagnosed each year in the
United States and the rate of diagnosed cases is increasing. Unfortunate-
ly, the cause ofMS and its rate of increase are unknown. There is no cure
for MS, although some therapies are available for those people with the
disease.
The diagnosis of MS is often challenging, causing frequent errors or
delays (Solomon et al., 2016). There is no single test that is performed
to diagnose the disease; rather, the diagnostic process involves physical
and neurological examinations, multiple MRIs, and a 6-month to 2-year
time frame prior to ﬁnal diagnosis, (Polman et al., 2011) which even
then may be a “soft” diagnosis. Collectively, the exhaustive process ofepartment of Cell & Molecular
ast Lansing, MI 48824, United
ence).
earch terms:Multiple Sclerosis,
. This is an open access article underdiagnosing (or ruling out) MS is costly and can adversely affect the pa-
tient as MS therapies may delayed during the diagnosing process.
A simple, objective bloodstream-based biomarker remains an
unmet clinical need (Polman et al., 2011). There have been recent re-
ports of blood-based diagnostics in the literature, although these
tests have suffered from either small patient numbers or very low
diagnostic sensitivity. Here, we evaluate the performance of a
blood-based lab test in distinguishing subjects with MS compared
to subjects with other, non-MS neurologic disease (ONDs) and
healthy controls. Speciﬁcally, we determined the amount of exoge-
nously added C-peptide bound to a sample of erythrocytes (ERYs)
obtained from the whole blood of people with MS to ERYs of healthy
controls and controls with ONDs.
2. Methods
The institutional review board at Michigan State University approved
all study protocols, and written informed consent was obtained from all
participants. Subjects were recruited from the Michigan State University
Department of Neurology and Ophthalmology Clinic, and comprised con-
secutive MS patients meetingMcDonald criteria, or ONDs. A convenience
sample of primarily lab personnel served as healthy controls.
Approximately 7.5mL ofwhole bloodwas obtained by venipuncture
into citrate-coated tubes under vacuum. All whole blood samples werethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Participant information and C-peptide uptake within each cohort. The values in parenthe-










Age, y 52.9 (17.4) 35.9 (16.3) 52.2 (13.5) 62.6 (15.0)
Female 63% 53.8% 75.6% 53.3%
C-peptide binding 1.99 (0.32) 3.51 (0.59) 2.23 (0.51)
p-Value to MS p b 0.001 p b 0.001
250 S.Y. Lockwood et al. / EBioMedicine 11 (2016) 249–252processed within 12 h after the blood draw. Processing started by
centrifuging the whole blood at 500g, and after removal of the buffy
layer by aspiration, the ERYs were washed with physiological salt solu-
tion (PSS) prior to determination of hematocrit using a hematocrit cen-
trifuge analyzer. Crude C-peptide was puriﬁed by high performance
liquid chromatography; 100% purity was conﬁrmed by mass spectrom-
etry and used to prepare 15 mL of a stock solution of approximately
8 μMC-peptide in distilled and deionized water (concentration veriﬁed
using a commercial ELISA kit). On the same day as an analysis of C-pep-
tide binding, aworking solution of C-peptide (800 nM)was prepared by
diluting 100 μL of the 8 μM stock solution to 1 mLwith distilled and de-
ionized water (DDW).
20 pmol of C-peptide (25 μL of the 800 nM solution) were added
to approximately 900 μL of PSS, followed by the immediate addition
of an aliquot of the puriﬁed ERYs (~100 μL, although amounts vary
based on hematocrit of the packed, puriﬁed ERYs) to result in a 7%
solution of ERYs in the ﬁnal C-peptide containing sample. After 2 h
of incubation at 37 °C, the sample was centrifuged at 500g. An aliquot
of the supernatant above the packed ERYs, as well as all standards,
was then diluted 1:50 in DDW and used as the sample in an ELISA
for C-peptide. The amount of C-peptide remaining in the supernatant
was measured, and by subtracting this amount from the 20 pmol
originally added to the sample, the amount bound to the ERYs was
calculated. C-peptide standards were prepared in PSS, diluted, and
measured in the same manner as the samples for quantitation, save
for the addition of the ERYs.
Thus, it is important to note that all sampleswere treated in an iden-
tical manner after the initial centrifugation of the whole blood. Incuba-
tion times and temperatures were identical for all samples (MS, OND,
and controls); calibrationswere performedwith standard C-peptide so-
lutions prior to analysis of samples.Fig. 1.Mean C-peptide uptake for control cohorts andMS patients. Approximately 7mL ofwhol
of these ERYs are added to a buffer that contains albumin and C-peptide. After an incubation per
via ELISA. The amount of C-peptide bound to the ERYs is obtained by subtracting the amount of
each data set is shown in the bar graph in themiddle. The ERYs from the healthy controls (n=
75) bound an average of 2.23± 0.51 pmol. The ERYs fromMS patients (n= 53) bound a signiﬁ
with an average of 3.51±0.0.59 pmol. Error bars represent standard deviations. The smaller do
each participant.The average C-peptide ± standard deviation is reported for all pa-
tient groups and statistical signiﬁcance is reported for all groups using
Student's t-test with associated p-values.
3. Results
3.1. Participant Data
Table 1 shows a breakdown of the 200 participants, 86 subjects had
MS (68% female, average age of 52 years, average disease duration
14.1 years, 76% treated with disease modifying therapies). Participants
with ONDs comprised 75 of the participants (46% female, average age
63 years). The remaining 39 study participants were healthy controls
(54% female, average age of 36 years).
3.2. C-peptide Binding to ERYs
The average binding of C-peptide to ERYs was 3.51 ± 0.59 pmol in
MS subjects (n = 86), higher than the 2.23 ± 0.51 pmol in subjects
with ONDs (n= 75; p b 0.001), or the 1.99± 0.32 pmol in healthy con-
trol (n = 39; p b 0.001), all statistically different (p b 0.001); (Fig. 1).
Among the subcohort of subjects with ONDs, the subjects with myas-
thenia gravis (n=7) demonstrated a tight cluster of elevated C-peptide
binding of 2.72±0.31 pmol; when these subjects are removed from the
data set, the average binding for the ONDs is 2.16 ± 0.52 pmol with
greater separation from the MS cohort.
While the data reported in this study is well-powered, a weakness
may be in the age differences between the controls and theMS patients.
Therefore, we evaluated the C-peptide uptake results as a function of
subject age and duration of disease. These results, shown in Fig. 2, clear-
ly show there is no correlation between C-peptide uptake by the cells
and subject age or how long the subject has had MS.
In addition to age and disease duration, data was also evaluated
based on any disease modifying therapies administered to the MS pa-
tients. These data were obtained for the 86 patients with MS and, as
shown in Table 2 below, there was no signiﬁcant difference between
the 16 patients with MS on no disease modifying therapies and the re-
maining 70 patients on some form of modifying therapy.
3.3. Diagnostic Evaluation of C-peptide Uptake
The potential for C-peptide binding to ERYs as an in vitro diagnostic
is strengthened upon evaluation of common diagnostic analysis tools. Ae blood is drawn by venipuncture, followed by centrifugation to pellet the ERYs. An aliquot
iod, the ERYs are centrifuged and the supernatant is analyzed for remaining, free C-peptide
C-peptide in the supernatant from the C-peptide originally added (20 pmol). Themean of
86) had an average C-peptide binding of 1.99 ± 0.32 pmol. The ERYs from the ONDs (n=
cantly higher amount (p b 0.001) than both the healthy and non-MS neurological controls,
t plot on the right is presented in order to show the individual C-peptide binding values for
Fig. 2. C-peptide uptake for MS patients based on age of subject and disease duration. C-peptide uptake was analyzed based on the age of the MS subject (n = 84 subjects reporting, left
ﬁgure) or theduration of the disease (n=54 subjects reporting, right ﬁgure). The correlation, provided by the values of coefﬁcient of determinationwithin theﬁgures,was not statistically
different from zero at 95%.
251S.Y. Lockwood et al. / EBioMedicine 11 (2016) 249–252receiver-operating characteristic (ROC) curve, a plot of the true positive
rate as a function of false positive rate, was constructed and is shown in
Fig. 3. Here, ROC curves can be used to determine C-peptide binding
thresholds resulting in the highest diagnostic odds ratio (DOR). The
DOR is derived from positive and negative likelihood ratios; the positive
likelihood ratio is calculated as the sensitivity/(1-speciﬁcity) and the
negative likelihood ratio is the speciﬁcity/(1-sensitivity). The DOR is
the quotient of likelihood ratios at various C-peptide binding values.
For our test, the optimum DOR (481) occurred when using 3.04 pmol
of C-peptide as the threshold value between predicting whether or
not a patient had MS. At this value of 3.04, the sensitivity was 98.3%
and the speciﬁcity was 89.5%.
4. Discussion
C-peptide is secreted in equal amounts with insulin from pancreatic
β-cell granules in vivo. Since its discovery in the late 1960’s, (Rubenstein
et al., 1969) C-peptide has been regarded as a biologically inactive spe-
cies once secreted from the β-cell granules (Luzi et al., 2007). In fact,
other than facilitating the insulin production process, many believe C-
peptide to be useful only as a biomarker for insulin production in pa-
tients with type 1 diabetes, due in large part to its longer half-life in
the bloodstream (~30min) in comparison to insulin (b5min). Further-
more, no ERY C-peptide receptor has been identiﬁed, and the mecha-
nism of ERY C-peptide uptake remains unknown.
However, since the mid-1990’s, there have been numerous studies
reporting beneﬁcial effects of C-peptide replacement therapy to animals
and humans with type 1 diabetes (Nordquist et al., 2008; Sima, 2003;
Sima and Kamiya, 2004; Wahren et al., 2007). Many of these cellular
and tissue effects involve improvements in blood ﬂow (Forst et al.,
2000; Forst and Kunt, 2004; Kunt et al., 1999). These studies reporting
an improvement of overall blood ﬂow inspired our group to investigate
and report that C-peptide enhances the ability of ERYs to release aden-
osine triphosphate (ATP), a well-established stimuli of the potent vessel
dilator andmediator of blood ﬂow, nitric oxide (NO). During the course
of our studies, we also reported that the ability of C-peptide to stimulate
increased ERY-derived ATP also required zinc and serum albumin
(Meyer et al., 2008; Liu et al., 2015). While C-peptide binds to the cell
in the presence of albumin, there are no biological effects on the cellTable 2
Participant information and C-peptide uptake among the 86 MS patients based on disease mod
None Glatiramer acetate Interferon Fingolimod
Uptake average 3.46 3.48 3.64 3.55
Std dev. 0.43 0.63 0.80 0.40
N 16 24 21 2
% 18.6% 28.0% 24.4% 2.2%unless zinc is delivered along with the C-peptide (Liu et al., 2015). In
fact, the ratio of C-peptide to zinc delivery to the cells is 1:1. Recently,
others have shown enhanced effects of C-peptide if supplemented
with zinc prior to in vivo delivery (Slinko et al., 2014).
Although we are investigating potential links between these ﬁnd-
ings and currently hypothesized models of MS pathobiology, ERY stud-
ies in MS patients are not without precedence. A report in the 1960s
(Raczkiewicz and Leyko, 1966) documented enhanced production of
“adenine nucleotides” from ERYs of MS patients after an oral glucose
challenge, and we reported an increase in ATP release from the ERYs
of MS patients versus healthy controls (Letourneau et al., 2010). In ac-
cordance with zinc, Dore-Duffy et al. demonstrated that MS ERY mem-
branes have a higher zinc to cholesterol ratio than control patients (Ho
et al., 1986; Dore-Duffy et al., 1983). Reports of normal plasma insulin
levels of people with MS suggest that insulin and C-peptide secretions
from the pancreatic β-cells of people with MS are not elevated. Collec-
tively, it was hypothesized that the increased production of the adenine
nucleotides and the increased membrane zinc levels may be due to in-
creased delivery of zinc to the MS ERY by C-peptide.
ERY C-peptide binding in the cohort of MS subjects was signiﬁ-
cantly higher than either the ONDs (p b 0.025) or healthy controls.
To date, we have analyzed 75 patients with non-MS neurologic dis-
eases including leukodystrophy, myasthenia gravis (MG), optic neu-
ropathy, and Parkinson's disease. While the average erythrocyte C-
peptide binding of the OND subjects was higher than the healthy
controls (p b 0.025), it remained signiﬁcantly lower than theMS sub-
jects. Using a cutoff of 3.04 pmol of C-peptide binding, the sensitivity
was 98.3% with a speciﬁcity of 89.5%. C-peptide uptake was indepen-
dent of age, disease duration, or disease-modifying therapy; there
was also no statistical difference in C-peptide uptake between MS
patients on a disease modifying therapy and MS patients who were
not on a therapy.
The subcohort with myasthenia gravis MG (n = 7) is small, but, in-
triguingly, demonstrated higher C-peptide binding than the other OND
subjects (p b 0.01); excluding MG subjects from this subcohort pro-
duced greater separation from theMS subjects. Due to C-peptide's asso-
ciation with diabetes, it should also be noted that, within our data set, 4
of the participants (1 control, 3 OND) had type 2 diabetes. While
they comprise a small percentage of our 200 patient study, the averageifying therapy.
Teriﬂunomide Natalizumab Dalfampridine Dimethyl fumarate
3.72 3.59 3.38 3.41
0.32 0.26 0.29 0.28
5 5 3 10
5.4% 5.4% 3.2% 11.8%
Fig. 3. Evaluation of C-peptide uptake as a potential diagnostic tool. An ROC curve showing the true positive rate (sensitivity) as a function of the false positive rate (1-speciﬁcity) is shown
on the left. The area under the curve for this curve is 0.97; typically, a useful diagnostic has an AUC of about 0.80. The data on the right represent various diagnostic odds ratios (DOR) at C-
peptide uptake values. The maximum DOR occurred at an uptake value of 3.04 pmol of C-peptide; at this uptake value, the sensitivity and speciﬁcity of the test were 98.3% and 89.5%,
respectively.
252 S.Y. Lockwood et al. / EBioMedicine 11 (2016) 249–252C-peptide uptake for these patients was b1 pmol. More measurements
are needed to reach meaningful conclusions, especially evaluating pa-
tients with both diabetes andMS (a rare but sometimes presenting con-
dition), but preliminarily, the ERYs of patients with diabetes alone
appear to bind less C-peptide, and therefore would not result in false
positives in our test.
Further investigation using this methodology among subjects with
MS accounting for such variables as MRI and clinical status, in addition
to other neurologic, autoimmune, and inﬂammatory diseases is ongo-
ing. In addition, validation studies will also be required if this test is to
be offered as an approved in vitro diagnostic. We are currently working
with regulatory agencies on the design and implementation of a larger
validation study. This pilot study demonstrates the potential of C-pep-
tide binding to ERYs as a possible test to assist in the diagnosis of MS,
and has the advantages of being minimally invasive, employing widely
available reagents, and rapid return of results.
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